Statement of Changes in Beneficial Ownership (4)
November 04 2021 - 4:03PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
AULT MILTON C III |
2. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc.
[
ALZN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
3802 SPECTRUM BOULEVARD, SUITE 112C |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/2/2021 |
(Street)
TAMPA, FL 33612
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 11/3/2021 | | M(1) | | 100000 | A | $0 | 250000 | D | |
Common Stock | | | | | | | | 6720388 | I | By Digital Power Lending, LLC (2) |
Common Stock | | | | | | | | 15000000 | I | By Ault Life Sciences, Inc. (3) |
Common Stock | | | | | | | | 10000000 | I | By Ault Life Sciences Fund, LLC (4) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Options (Right to Buy) | $0.0004 | 11/3/2021 | | M | | | 100000 | (5) | 4/29/2026 | Common Stock | 100000 | $0 | 2250000 | D | |
Call Option (right to buy) | $2.50 | 11/2/2021 | | P | | 50 | | (6) | 5/20/2022 | Common Stock | 5000 | $79.5094 | 50 | I | By Digital Power Lending, LLC (2) |
Call Option (right to buy) | $2.50 | 11/3/2021 | | P | | 100 | | (6) | 5/20/2022 | Common Stock | 10000 | $77.5094 | 150 | I | By Digital Power Lending, LLC (2) |
Call Option (right to buy) | $2.50 | | | | | | | (6) | 2/18/2022 | Common Stock | 40000 | | 400 | I | By Digital Power Lending, LLC (2) |
Call Option (right to buy) | $2.50 | | | | | | | (6) | 2/18/2022 | Common Stock | 102000 | | 1020 | I | By Digital Power Lending, LLC( (2) |
Call Option (right to buy) | $10.00 | | | | | | | (6) | 2/18/2022 | Common Stock | 40000 | | 400 | I | By Digital Power Lending, LLC (2) |
Call Option (right to buy) | $7.50 | | | | | | | (6) | 2/18/2022 | Common Stock | 5000 | | 50 | I | By Digital Power Lending, LLC (2) |
Explanation of Responses: |
(1) | This transaction was effected pursuant to Rule 16b-3 with shares of common stock received upon the exercise of stock options. |
(2) | Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL. |
(3) | Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc. |
(4) | Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC. |
(5) | The stock options exercised in this transaction were fully vested and exercisable as of the transaction date. |
(6) | The security listed is an exchange-traded option contract. Exchange-traded options are immediately exercisable and remain exercisable until expiration. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
AULT MILTON C III 3802 SPECTRUM BOULEVARD, SUITE 112C TAMPA, FL 33612 |
| X |
|
|
Signatures
|
/s/ Milton C. Ault, III | | 11/4/2021 |
**Signature of Reporting Person | Date |
Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alzamend Neuro (NASDAQ:ALZN)
Historical Stock Chart
From Jul 2023 to Jul 2024